EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation by Yee, Della et al.
Mu et al. Epigenetics & Chromatin           (2018) 11:71  
https://doi.org/10.1186/s13072-018-0242-9
RESEARCH
EZH2 variants differentially regulate 
polycomb repressive complex 2 in histone 
methylation and cell differentiation
Weipeng Mu, Joshua Starmer, Della Yee and Terry Magnuson* 
Abstract 
Background: Polycomb repressive complex 2 (PRC2) is responsible for establishing and maintaining histone H3K27 
methylation during cell differentiation and proliferation. H3K27 can be mono-, di-, or trimethylated, resulting in differ-
ential gene regulation. However, it remains unknown how PRC2 specifies the degree and biological effects of H3K27 
methylation within a given cellular context. One way to determine PRC2 specificity may be through alternative splic-
ing of Ezh2, PRC2’s catalytic subunit, during cell differentiation and tissue maturation.
Results: We fully characterized the alternative splicing of Ezh2 in somatic cells and male germ cells and found that 
Ezh’s exon 14 was differentially regulated during mitosis and meiosis. The Ezh2 isoform containing exon 14 (ex14-Ezh2) 
is upregulated during cell cycle progression, consistent with a role in maintaining H3K27 methylation during chroma-
tin replication. In contrast, the isoform lacking exon 14 (ex14D-Ezh2) was almost exclusively present in spermatocytes 
when new H3K27me2 is established during meiotic differentiation. Moreover, Ezh2’s transcript is normally controlled 
by E2F transcription activators, but in spermatocytes, Ezh2’s transcription is controlled by the meiotic regulator MYBL1. 
Compared to ex14-EZH2, ex14D-EZH2 has a diminished efficiency for catalyzing H3K27me3 and promotes embryonic 
stem cell differentiation.
Conclusions: Ezh2’s expression is regulated at transcriptional and post-transcriptional levels in a cellular context-
dependent manner. EZH2 variants determine functional specificity of PRC2 in histone methylation during cell prolif-
eration and differentiation.
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Background
Polycomb repressive complex 2 (PRC2) catalyzes mono-, 
di-, and trimethylation of histone H3 lysine 27 (H3K27) 
and functions as a key epigenetic regulator for normal 
development and diseases. The three forms of H3K27 
methylation are mutually exclusive and form spatially 
defined genomic domains. Monomethylated H3K27 
(H3K27me1) is enriched in the gene bodies of active 
genes, indicative of its involvement in gene activation 
[1–4]. In contrast, dimethylated H3K27 (H3K27me2) 
primarily resides within large intergenic and intragenic 
chromatin domains (50–70% of H3 tails) [5, 6], possibly 
exerting a protective role by preventing non-cell-type-
specific enhancer use [3]. Lastly, trimethylated H3K27 
(H3K27me3) is widely present in the promoter regions 
of silenced genes and thought to provide PRC2 with a 
role in transcriptional repression [7, 8]. PRC2 catalyzes 
H3K27me1 and H3K27me2 relatively efficiently com-
pared to H3K27me3 [9]. During cell cycle progression, 
H3K27me1 and me2 are rapidly incorporated into chro-
matin after DNA synthesis, but the restoration of normal 
H3K27me3 levels is delayed [10–12]. In light of PRC2’s 
versatility in histone methylation and gene regulation, 
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it is important to understand how this complex is spati-
otemporally orchestrated to load the appropriate methyl 
groups onto targeted genomic loci during cell prolifera-
tion and differentiation.
The PRC2 complex is composed of core subunits (EED, 
EZH1/2, SUZ12, and RBBP4/7) required for enzymatic 
activity, and accessory subunits (PCLs, JARID2, AEBP2) 
that regulate the recruitment and activity of PRC2 [7]. 
Recent studies suggest that accessory PRC2 components 
regulate DNA binding, methyltransferase activity and the 
spread of methylation marks on the genome. The selec-
tive incorporation of accessory subunits leads to the for-
mation of PRC2 subcomplexes, PRC2.1, characterized by 
the incorporation of AEBP2 and JARID2, and PRC2.2, 
characterized by mutually exclusive binding of one of the 
three polycomb-like homologs (PCLs) PHF1, PHF19, and 
MTF2 [13]. However, these PRC2 variants only exhibit 
subtle differences in histone methylation and do not 
explain the locus-specific H3K27 methylation across the 
whole genome. In contrast, with the exception of EED, 
little is known about the roles that the core subunits may 
play in determining PRC2’s flexibility in histone methyla-
tion. EED undergoes alternative translation to yield four 
protein products; however, this diversity does not control 
the number of methyl groups added to H3K27 since each 
isoform is sufficient to generate all three H3K27 methyla-
tion marks [14].
PRC2 plays two major roles in histone methylation: it 
can maintain existing H3K27 methylation marks so that 
they are propagated to daughter cells and it can establish 
new H3K27 methylation sites. During cell proliferation, 
the E2F family of cell cycle transcription factors enhances 
the expression of Ezh2, which duplicates H3K27 meth-
ylation during cell proliferation [15]. During cell differen-
tiation, PRC2 establishes new H3K27 methylation sites, 
especially in male germ cells. These new H3K27 meth-
ylation marks are introduced into the genome to deter-
mine the cell-type-specific transcriptome [16]. In this 
case, PRC2’s recruitment to specific loci for methylation 
appears to be a more complicated process, potentially 
involving noncoding RNAs, sequence-specific transcrip-
tion factors, and/or PRC2-interacting proteins with affin-
ity for CpG-rich DNA elements [17]. Our previous results 
demonstrate that EED, EZH2, and SUZ12 are dramati-
cally upregulated in pachytene spermatocytes [16], sug-
gesting the germ cell-specific PRC2 complex has a role in 
establishing H3K27 methylation during meiotic progres-
sion. Therefore, it is crucial to understand how PRC2 can 
distinguish these two different types of histone methyla-
tion coupled with cell proliferation and differentiation.
EZH2 may have a major role in determining PRC2’s 
differential methylation roles. It possesses multiple 
interaction domains for EED and SUZ12, facilitating the 
methyltransferase activity conveyed by its SET domain 
[18–20]. EZH1, a homolog of EZH2 encoded by a sepa-
rate locus [21], has much less methyltransferase activity 
and cannot substitute for EZH2 in histone methylation 
and related biological functions in many tissues [22]. 
Because other PRC2 subunits only have a subtle effect 
on EZH2 methyltransferase specificity, we speculate that 
EZH2’s variants themselves diversify PRC2’s functional 
roles in distinct methylation processes during cell prolif-
eration and differentiation.
Here, we identified multiple Ezh2 isoforms derived 
from alternative transcriptional splicing in various tis-
sues and cell types. Expressions of EZH2 variants that 
include or exclude exon 14 are differentially regulated 
via cell cycle or meiotic regulators, respectively, during 
mitosis and meiosis. The EZH2 isoform without exon 14 
(ex14D-EZH2) has a disrupted CXC domain and is the 
primary isoform found in spermatocytes. This isoform 
is responsible for the establishment of H3K27me2, but is 
less efficient at catalyzing H3K27me3. Moreover, exclu-
sive expression of ex14D-EZH2 in ES cells promotes their 
differentiation, indicated by precocious and enhanced 
expression of mesoderm genes. In contrast, the EZH2 
isoform with exon 14 (ex14-EZH2) is the most common 
isoform in proliferating cells and more efficient at cata-
lyzing H3K27me3. Our study suggests that the incorpo-
ration of specific EZH2 variants into the PRC2 complex 
controls the appropriate level and extent of H3K27 meth-
ylation in polycomb target loci during the establishment 
and maintenance of these epigenetic marks.
Results
Ezh2 pre‑mRNA splicing is differentially regulated 
during meiosis and mitosis
Ezh2 makes several distinct transcripts due to alterna-
tive splicing. Exons 4 and 14 can be skipped and exons 
3 and 8 can be truncated (Fig.  1a) [23]. To determine 
whether different Ezh2 transcripts are cell and tissue type 
specific, we profiled Ezh2 transcripts in different ages of 
testes, somatic tissues, embryos, and primary cell lines 
by RT-PCR. The Ezh2 transcripts that contain alternative 
splicing for exon 3 and exon 14 are found in many tissues 
and cultured cells (Fig. 1b). In contrast, transcripts con-
taining alternative splicing for exons 4 and 8 were barely 
detected (Additional file 1: Fig. S1). Thus, we focused on 
Ezh2 transcripts with variations in exons 3 and 14.
First, we examined Ezh2 and Ezh1 transcript levels 
during spermatogenesis. Ezh2 transcripts without exon 
14 (ex14D-Ezh2) were at a relatively low level in mitotic 
germ cell populations such as progenitors (E13.5 and 
E15.5) and spermatogonial stem cells (p5). However, this 
isoform was dramatically upregulated at the time of entry 
into meiosis (p10) and maintained at high levels during 
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Fig. 1 Ezh2 splicing is differentially regulated during meiosis and mitosis. a Schematic structure of the mouse Ezh2 gene and protein. Removal of 
exon 14 causes the disruption of the CXC domain. b RT-PCR analysis of alternative Ezh2 transcripts in mouse testis at different ages, tissues, embryos, 
and cell lines. c Quantitation of Ezh1 and Ezh2 transcripts during testis development by qPCR analysis. d Quantitation of the transcription of PRC2 
core components by qPCR analysis. e Quantitation of Ezh1 and Ezh2 transcripts during the cell cycle progression. f Western blot analysis of PRC2 
core components during the cell cycle progression
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the meiotic progression as shown in p19, 1-month and 
4-month testes. In contrast, the Ezh2 transcripts con-
taining exon 14 (ex14-Ezh2) were downregulated dur-
ing meiosis (Fig.  1b). The dynamics of exon 14-related 
alternative transcripts were verified by qPCR analysis 
(Fig. 1c). Transcription of PRC2’s core components, Eed, 
Suz12, and Rbbp4, also increased during germ cell matu-
ration (Fig. 1d), suggesting ex14D-EZH2 functions within 
the PRC2 complex during meiotic differentiation. In con-
trast, Ezh1 levels were consistent throughout germ cell 
development (Fig.  1c), indicating its expression is inde-
pendent of meiotic differentiation.
Because ex14-Ezh2 is abundant in mitotic germ cells 
and rapidly dividing ES cells and primary MEFs (Fig. 1b), 
we wanted to determine the dynamics of Ezh2 and Ezh1 
transcripts during mitosis. Thus, we synchronized pri-
mary MEFs at the G0/G1 phase by serum starvation and 
then released them into the S and G2/M phases with 
serum supplementation. In comparison with meiosis, 
ex14-Ezh2, but not ex14D-Ezh2, was remarkably elevated 
during mitotic progression (Fig. 1e). The Ezh2 transcripts 
with a full exon 3 (ex3-Ezh2) or a truncated exon 3 (ex3T-
Ezh2) were both upregulated. EZH2, EED, and SUZ12 
protein levels also increased in mitotic cells (Fig.  1f ). 
Ezh1 expression decreased with the cell cycle activation, 
which is consistent with the high expression of Ezh1 in 
mature tissue but low in proliferating tissues [21]. These 
results indicate that Ezh variants are differentially regu-
lated during meiosis and mitosis.
ex14D‑Ezh2 transcription is independent of E2F 
regulation and responsible for establishing H3K27me2 
in spermatocytes
Ezh2 expression is typically regulated by the E2F family 
of transcription factors, among which E2F1-3 function 
as activators to promote Ezh2 transcription in proliferat-
ing cells [15]. To assess transcriptional reprogramming of 
E2f1-3 during spermatogenesis, we analyzed their chro-
matin state and expression levels in germ cells isolated 
from different ages of testes. We found repressive histone 
marks, H3K27me3, accumulated around E2f2 and E2f3’s 
transcriptional start sites in germ cells over time, with the 
most H3K27me3 detected at p30. This was the opposite 
of the accumulation of active marks, H3K4me3 (Fig. 2a–
c). Accordingly, E2f1-3 transcription was active in p9 tes-
tes with ample spermatogonial populations but repressed 
in meiocyte-enriched p17 testes (Fig.  2d–f), suggesting 
that E2F does not contribute to upregulated Ezh2 expres-
sion during meiotic progression.
Meiotic ex14D-Ezh2 expression occurs at a time when 
new histone marks are established during cell differen-
tiation, suggesting that it may have a role in this process. 
Thus, we characterized H3K27 methylation patterns in 
different populations of spermatocytes during meio-
sis. There were no significant differences in H3K27me1 
and H3K27me3 levels between early stage (leptonema) 
and late stage (pachynema) spermatocytes. However, 
H3K27me2 levels were strikingly elevated during the 
zygonema to pachynema transition (Fig.  2g), which is 
consistent with the upregulation of EZH2 in pachytene 
spermatocytes [16] and with ex14D-Ezh2 transcripts in 
pachynema-enriched p19 testes (Fig. 1b, c). These results 
suggest that ex14D-Ezh2 transcription and processing 
occur in a cellular context-dependent manner for estab-
lishing H3K27me2.
MYBL1 activates ex14D‑Ezh2 expression in spermatocytes
Because ex14D-Ezh2 expression was increased dur-
ing meiosis, we speculated that it was regulated by 
meiosis-specific transcriptional activators. We did not 
observe any active chromatin marks, such as H3K4me3, 
H3K27ac, or ATAC-seq peaks, throughout the 
ENSEMBL-annotated transcript for ex14D-Ezh2 (Addi-
tional file  2: Fig. S2a), suggesting that transcription of 
this isoform initiated from outside of the transcript. We 
predicted that the other two ENSEMBL-annotated non-
coding exons, ex1a and ex1b, which are surrounded by 
H3K4me3 and H3K27ac in testis, could encode ex14D-
Ezh2’s 5′ UTR (Fig. 3a). The first noncoding exon, ex1a, 
contains an E2F1 binding motif, as predicted by HOMER 
(Fig. 3a), that is bound by E2F1 as determined by a ChIP-
seq analysis, in proliferating human Hela S3 cells (Addi-
tional file  2: Fig. S2b) (ENCODE/Peggy Farnham). This 
suggests the existence of a promoter in that region drives 
the cell cycle-related expression of ex14-Ezh2 and not 
ex14D-Ezh2, since ex14D-Ezh2 transcription is not pro-
moted by E2F1. Thus, we suspected that the second non-
coding exon, ex1b, encoded the 5′ UTR of ex14D-Ezh2 
in testis. To test this, we performed RT-PCR analysis to 
amplify cDNA fragments spanning exon 1b to exon 15, 
and then cloned the amplicons into plasmids for geno-
typing the alternative splicing at exon 3 and ex14 by Col-
ony PCR assays (Fig.  3b). We found that the amplicons 
derived from ex1b excluded exon 14, demonstrating ex1b 
encodes the 5′ UTR of ex14D-Ezh2. ex14D-Ezh2 did not 
have preference for the alternative splicing of exon 3.
Because ex1b encodes the 5′ UTR of ex14D-Ezh2, we 
performed motif analysis with HOMER to search for 
transcription factors that could bind near it. This analy-
sis predicted that MYBL1, a master regulator of male 
meiosis [24], had a DNA binding site upstream of ex1b, 
and binding was confirmed by MYBL1 ChIP-seq analysis 
(Fig. 3a) [25]. Consistent with Ezh2 expression in meio-
sis, MYBL1 was at a low level in leptotene and zygotene, 
and significantly elevated in pachytene and diplotene 
spermatocytes (Fig. 3c). MYBL1’s role as a transcriptional 
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Fig. 2 The expression of ex14D-Ezh2 in spermatocytes is responsible for the establishment of H3K27me2. a–c The dynamics of H3K27me3 and 
H3K4me3 enrichment on E2f1-3 during spermatogenesis. Spermatocytes were isolated from postnatal day 12 (p12), 17 (p17), and 30 (p30) testes 
for ChIP-seq analysis. d–f RNA-seq analysis of E2f1-3 transcription in germ cells purified from p9 and p17 testes. The representative sample tracks for 
each time point are presented here. g Assessment of H3K27 methylation in different meiotic cell populations. Cryosections of 4-month-old testis 
were immunostained for indicated proteins. (l) leptotene spermatocytes; (z) zygonema; (p) pachynema; (d) diplonema. Scale bar: 20 μm
Page 6 of 14Mu et al. Epigenetics & Chromatin           (2018) 11:71 
activator of Ezh2 in germ cells is further supported by 
the evidence that a Mybl1 knockout in testis caused the 
downregulation of Ezh2 transcription [24]. MYBL1 was 
also enriched in the promoter regions of Eed and Suz12 
(Additional file 2: Fig. S2c, d), indicative of its function-
ing as a PRC2 regulator during spermatogenesis. Thus, all 
of these data suggest that MYBL1 activates ex14D-Ezh2 
expression from ex1b in spermatocytes.
ex14D‑EZH2 has preferential activity toward H3K27me2 
but not H3K27me3 and promotes ES cell differentiation
To explore the roles of ex14D-EZH2 in H3K27 methyla-
tion and cell differentiation, we generated ES cell lines 
in which Ezh2’s exon 14 was disrupted using CRISPR-
Cas9. The in/del mutation on exon 14 caused a reading 
frame shift, resulting in the disruption of the SET domain 
in ex14-EZH2. Thus, only the alternatively spliced 
ex14D-EZH2 isoform was functional (Fig.  4a). EZH2 
protein levels in ex14D-Ezh2 cell lines were around 30% 
of those in control cell lines, demonstrating the loss of 
ex14-EZH2 (Fig.  4b). Consistent with the EZH2 reduc-
tion, H3K27me3 levels were decreased by 67% in the 
mutant cell lines. However, there was no reduction in 
H3K27me2 levels in ex14D-Ezh2 ES cells compared to 
the controls (Fig.  4c). To assess if ex14D-EZH2 could 
still saturate EZH2 binding sites, we performed ChIP-
seq analysis on EZH2 and found that the enrichment of 
EZH2 was decreased in the target genes in ex14D-Ezh2 
cells (Fig.  4d). Although EZH2 protein was decreased 
by 70%, ex14D-EZH2 still methylated 76% of the target 
genes (4440 out of 5811 genes) by H3K27me3 (Fig.  4e). 
We quantified the enrichment of H3K27me3 in two cate-
gories of genes: genes with H3K27me3 marks all over the 
gene body, including Hoxa10, Hoxd9, Bmp6 and Pax7, 
and genes with this mark around TSS region, such as 
Elavl3, Shc3, and Runx2. Both groups of genes were less 
Fig. 3 The expression of ex14D-Ezh2 is activated by MYBL1. a The epigenetic signature and transcription factor binding motifs around Ezh2’s 5′ 
UTR. HOMER-motif analysis detected E2F1 binding sites within the 300 bp upstream of the ex1a TSS. ex1a is the first exon that is known for coding 
ex14-Ezh2’s 5′ UTR. ex1b is a putative exon for ex14D-Ezh2’s 5′ UTR. b Characterization of ex14D-Ezh2’s 5′ UTR. Primer p1 and p2 were used to amplify 
the DNA sequence coding the transcripts initiated from the ex1b 5′ UTR. The amplicons were cloned into vectors and transformed into bacteria. The 
alternative splicing events were assessed by genotyping single colonies. c Cryosections of p30 testes were immunostained with indicated proteins. 
Scale bar: 20 μm
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methylated when only ex14D-EZH2 was present (Fig. 4f ). 
Thus, ex14D-EZH2 maintains normal levels of H3K27 
dimethylation but not H3K27 trimethylation.
PRC2 can establish new H3K27me3 marks for repro-
gramming the transcriptome during cell lineage specifi-
cation. De Novo trimethylation of H3K27 occurs during 
Fig. 4 ex14D-EZH2 participates in establishing and maintaining H3K27 methylation and promotes ES cell differentiation. a A schematic of how 
ex14D-Ezh2 ES cell lines were created by CRISPR-Cas9. b Western blot analysis of EZH2 proteins in ex14D-Ezh2 cells. c Western blot analysis of 
histone H3K27 methylation levels in ex14D-Ezh2 ES cells. d A smear plot showing ex14D-EZH2 is not sufficient for saturating EZH2 targeting genes. 
e A Venn diagram showing that ex14D-EZH2 binds to the majority EZH2 targets. f Assessment of H3K27me3 maintenance on key developmental 
genes in ex14D-Ezh2 ES cells by ChIP-PCR analysis. g Assessment of the newly introduced H3K27me3 marks during ES cell differentiation. h qPCR 
analysis of the expression of mesoderm marker genes during LIF withdrawal-induced ES cell differentiation
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retinol acid-induced ES cell differentiation [26]. In RA-
treated ES cells, we found that ex14D-EZH2 introduced 
new H3K27me3 marks to Fgf4’s promoter and intron, 
Utf1, and Nphs1, but at reduced levels (Fig. 4g). In con-
trast, Ezh2 knockout cells failed to establish those marks 
during ES cell differentiation, suggesting that EZH1 can-
not establish new H3K27me3 marks even though it can 
partially rescue the maintenance of H3K27me3 during 
cell proliferation as shown in Fig. 4f.
Because EZH2 is required for mouse ES cell differen-
tiation [27], we tested if ex14D-Ezh2 had a specific role 
in this process. Withdrawal of leukemia inhibitory factor 
(LIF) induces differentiation of mouse ESCs into various 
embryonic and extraembryonic lineages [28]. To under-
stand to what degree ex14D-EZH2 contributes to ES cell 
differentiation, we measured the expression of mesoderm 
marker genes activated by LIF withdrawal in Ezh2KO, 
ex14D-Ezh2, and control cells. As expected, in Ezh2 
knockout cells, Brachyury, Eomes, and Mixl1 failed to 
activate. In contrast, Brachyury, Eomes, and Mixl1 were 
all upregulated in ex14D-Ezh2, and control cells. Intrigu-
ingly, exclusive expression of ex14D-Ezh2 led to preco-
cious expression of these marker genes at higher levels 
(Fig.  4h). In conclusion, these data suggest that ex14D-
Ezh2 promotes ES cell differentiation.
EZH1 and EZH2 variants have differential activity 
in catalyzing trimethylation of H3K27
The reduction in H3K27me3 in ex 14D-Ezh2 ES cells 
(Fig.  4c) could be due to the decreased EZH2 levels 
(Fig.  4b) and/or the weak methyltransferase activity of 
ex14D-EZH2 toward H3K27me3. To compare the meth-
yltransferase activity of EZH1 and EZH2 variants, we 
ectopically expressed Ezh1 and Ezh2 isoforms with dif-
ferent combinations of alternative splicing on exon 3 
and exon 14 in Ezh2- and Ezh1/2-deficient ES cells. The 
Ezh2KO caused dramatic decreases in H3K27me2 and 
H3K27me3, but did not affect H3K27me1 levels. The 
Ezh1/2 double knockout (EzhDKO) depleted H3K27me2 
and H3K27me3 even more than the Ezh2KO in addi-
tion to reducing H3K27me1 (Additional file 3: Fig. S3a). 
Because Western blot analysis showed that the EZH2 
isoforms, in the absence of exon 14, were expressed at 
relatively low levels (Additional file 3: Fig. S3b), we used 
immunofluorescence to assess the H3K27 methylation 
levels in single cells. We used the same exposure times, 
contrast and brightness adjustments to ensure EZH2 
intensity was comparable among different variants. We 
found that EZH2 variants containing exon 14 can estab-
lish all three forms of H3K27 methylation (Fig.  5 and 
Additional file 3: Fig. S3c, d). In contrast, the absence of 
exon 14 severely impaired EZH2’s ability to trimethylate 
H3K27 (Fig. 5c and Additional file 3: Fig. S3d), but did not 
affect the mono- and dimethylation (Fig. 5a, b, and Addi-
tional file  3: Fig. S3c). Ezh1 also exhibited weak activity 
toward tri-, but strong H3K27 mono- and dimethylation 
activity in ES cells (Fig. 5 and Additional file 3: Fig. S3c, 
d). Thus, EZH1 and EZH2 variants have differential activ-
ity for methylating H3K27.
Since EZH variants have different abilities with respect 
to H3K27 methylation, we asked if the physical interac-
tions between EZH variants and core subunits or acces-
sory subunits regulate their catalytic specificity and 
activity. EZH2 in ES cells and ex14D-EZH2 in spermato-
cytes can interact with SUZ12 and EED (Additional file 4: 
Fig. S4a). In HEK293T cells cotransfected with EZH vari-
ants and PRC2 subunits, we found that PHF1, PHF19, 
JARID2, and RBBP4 were part of the protein complexes 
containing either ex14D- or ex14-Ezh2 (Additional file 4: 
Fig. S4b, c). These results suggest that EZH variants do 
not selectively exclude these subunits when assembled 
into PRC2. Taken together, the alteration of EZH2’s 
CXC domain determines its SET domain capacity in 
H3K27me3.
Discussion
For most histone methylation processes, such as 
H3K9me and H3K4me, multiple methyltransferases par-
ticipate in loading a specific number of methyl groups 
onto histones, resulting in gene regulation [29]. However, 
the three forms of H3K27 methylation are mostly exe-
cuted through EZH2-PRC2. H3K27me1 and H3K27me2 
are found throughout the chromosomes, but without the 
coexistence of PRC2 by ChIP-seq analysis [3]. In con-
trast, chromatin domains marked by H3K27me3 are also 
abundant in PRC2 binding [16]. This suggests that PRC2 
uses differential mechanisms to control the methyla-
tion reaction on its targeting loci. Although other PRC2 
subunits either regulate or are essential for EZH2’s enzy-
matic activity, they do not determine the level of meth-
ylation (i.e., H3K27me1, me2 and me3). EZH1 and EZH2 
variants contain multiple domains that mediate physical 
interactions with most of PRC2’s subunits and ncRNA 
[30]. We hypothesize that the diversity in EZH1 and 
EZH2 proteins regulate H3K27 methylation and estab-
lish and maintain these epigenetic marks. By examining 
the dynamics of Ezh2 transcripts during cell proliferation 
and differentiation, we showed that EZH2 variants with 
and without exon 14 mechanistically regulated PRC2’s 
ability to load specific numbers of methyl groups onto 
histones.
Ezh2’s exon 14 encodes a CXC domain which precedes 
the SET catalytic domain and is characterized by three 
C-X(6)-C-X(3)-C-X-C motifs [31, 32]. Mutation of the 
cysteine in CXC domains impaired the methyltransferase 
activity in PRC2 [33] and overexpression of the protein 
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Fig. 5 EZH variants had different abilities to catalyze the trimethylation of H3K27. a–c Immunofluorescence analysis of H3K27me1, me2, and me3 in 
EzhDKO ES cells that were transfected with FLAG-tagged EZH variants, respectively. Scale bar: 20 μm
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interacting with a CXC domain in EZH2 can enhance 
H3K27 methylation [34]. Consistent with these two 
studies, ex14D-EZH2, which lacks two C-X(6)-C-X(3)-
C-X-C motifs in the CXC domain, exhibited diminished 
catalytic activity in H3K27me3. But this disruption of the 
CXC domain did not affect PRC2’s ability to mono- and 
di-methylate H3K27. We also found that nearly exclu-
sive expression of ex14D-Ezh2 is coincident to acquiring 
H3K27me2 in spermatocytes. This led us to speculate 
that Ezh2’s alternative splicing serves as a switch to con-
trol the methylation status on modified nucleosomes. 
Because EZH2 can convert H3K27me2 to H3K27me3 
[35, 36], ex14D-EZH2 in spermatocytes may help to 
maintain the H3K27me2 marks which fail to be trimeth-
ylated at genomic loci where silencing normally involves 
H3K27me3-independent mechanisms. Previous studies 
showed that the H3K27me3 marks accumulated on key 
developmental genes were not replaced by protamines in 
sperm [37, 38] and could be transmitted to the next gen-
eration for regulating embryonic gene expression [39]. 
Thus, it is important to maintain the genomic distribu-
tion of H3K27 methylation states in germ cells for epige-
netic inheritance.
EZH1 was thought to compensate for the absence of 
EZH2 in H3K27 methylation. But in our study, EZH1 
was unable to generate new H3K27me3 marks on target 
genes during cell differentiation. Also, overexpression of 
EZH1 did not rescue H3K27me3 in proliferating cells as 
ex14-EZH2 did, even though EZH1 and EZH2 are nearly 
identical in their CXC and SET domains. However, com-
pared to EZH2, EZH1 does not have a cell cycle-regu-
lated expression pattern, it shares less similarity in the 
N-terminal domains, and it promotes mRNA transcrip-
tion during cellular differentiation [40]. This indicates 
that the methylation activity of EZH1-PRC2 is regulated 
differently from EZH2-PRC2. In contrast to EZH2, EZH1 
is abundant in highly differentiated tissues and low in 
actively proliferating cells. It will be interesting to explore 
EZH1’s cell-type-specific interacting partners, which 
facilitate the recruitment onto chromatin and the activa-
tion of its methyltransferase activity.
EZH2 level is a determinant for its appropriate bio-
logical functions. Deficiency in EZH2 caused cell cycle 
arrest, senescence, and differentiation defects [15]. EZH2 
overexpression has been reported to promote cell pro-
liferation and neoplastic transformation [41]. Our find-
ings show that EZH2 expression is finely controlled at 
both transcriptional and post-transcriptional levels for 
producing suitable doses and isoforms of EZH2. To regu-
late transcription, cell-type-specific TFs and cell cycle-
related TFs cooperate to adjust EZH2 expression levels 
according to the cell’s differentiation and proliferation 
status. The levels of ex14D-EZH2 for generating new 
H3K27me in spermatocytes are much lower than EZH2 
for duplicating H3K27 methylation in highly prolifer-
ating ES cells (Additional file 4: Fig. S4d). The relatively 
low levels of ex14D-EZH2 in differentiating cells could 
serve as a mechanism for recovery of H3K27 methylation 
due to histone turnover occurring at a low rate [42] and, 
meanwhile, introducing new marks at specific genomic 
loci. For pre-mRNA processing, each alternative splic-
ing event is controlled by multiple RNA binding proteins 
(RBPs), the combined action of which creates a distribu-
tion of alternatively spliced products in a given cell type 
[43]. In renal cancer cells, the splicing factor SF3B3 stim-
ulates the inclusion of exon 14 in Ezh2 transcripts [44]. 
During spermatogenesis, the splicing landscape is glob-
ally reprogrammed in the mitotic-to-meiotic transition 
during the germ cell cycle [45]. We reason that spermato-
cytes express a meiosis-specific array of RBPs, which give 
rise to the skewed production of ex14D-Ezh2 transcripts.
We propose a model for regulating EZH2 variants to 
establish and maintain H3K27 methylation (Fig. 6). Dur-
ing mitosis, the E2F cell cycle regulators stimulate ex14-
EZH2-PRC2 expression at high levels to duplicate H3K27 
methylation marks across the genome in progeny cells. 
During meiosis, germ cell-specific transcription fac-
tors and splicing factors control exclusive expression of 
ex14D-EZH2. The low levels of ex14D-EZH2-PRC2 are 
active for dimethylation of H3K27, but with decreased 
capability for H3K27me3, resulting in the faithful estab-
lishment of new H3K27me2 marks.
Conclusions
We revealed that Ezh2’s expression was differentially reg-
ulated at transcriptional and post-transcriptional levels 
during mitosis and meiosis. EZH2 isoforms have differ-
ent catalytic activity in mono-, di-, and trimethylation of 
H3K27. The incorporation of specific EZH2 variants into 
the PRC2 complex regulates the fidelity in the establish-
ment and maintenance of these epigenetic marks across 
the genome.
Materials and methods
RT‑PCR and qPCR
Total RNA was extracted from whole testis or isolated 
spermatocytes using TRIzol reagent (Invitrogen) fol-
lowed by an RNA cleanup step and on-column DNA 
digestion using Direct-zol™ RNA MiniPrep Kit (Zymo 
Research) according to the manufacturers’ instructions. 
cDNA was synthesized using ProtoScript II Reverse 
Transcriptase (NEB). Real-time qPCR analysis was per-
formed using SsoFast EvaGreen supermix (Bio-Rad) 
and CFX96 thermocycler (Bio-Rad) (Additional file  5: 
Table S1).
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ChIP‑seq
The ChIP-seq was performed as described [46]. Five mil-
lion mouse ES cells and 2.5  μg of H3K27me3 antibody 
(ab6002; Abcam) or 5  μl of EZH2 antibody (#5246, cell 
signaling) were used per IP. ChIP-seq libraries were pre-
pared according to Illumina instructions and sequenced 
on Illumina’s Genome Analyzer IIx or HiSeq2000 instru-
ment. Sequence reads were aligned to genomic sequence 
with Bowtie [47]. All mm10 genome annotations were 
obtained from the UCSC genome browser. HiddenDo-
mains [48] and MACSv2 [49] identified ChIP-seq enrich-
ment using 200  bp bins. Peak annotation was created 
by ChIPseeker [50] using only the peaks with posterior 
probabilities > 0.9. Reads at promoters, defined as a 1 kb 
window centered on the 5′ most TSS, were counted using 
htseq-count [51].
Cell culture
Mouse embryonic fibroblasts (MEFs) were cultured 
as described previously [52]. Primary MEFs were 
synchronized by serum starvation (0.2% FBS) for 2 days 
and then released into cell cycle by supplement with 10% 
FBS. The cells were harvested at the time points indi-
cated for RNA and protein extraction. HEK293 were cul-
tured in the same medium as MEFs and transfected with 
FLAG- or HA-tagged PRC2 subunits using calcium phos-
phate. The cells were collected 48 h post-transfection for 
protein extraction. Mouse E14 ES cells were cultured in 
Glasgow Minimum Essential Medium supplemented 
with 15% fetal bovine serum, 1.0  mM  l-glutamine, 
0.1  mM minimal essential medium-nonessential amino 
acids, 0.1  mM β-mercaptoethanol, and leukemia inhibi-
tory factor. The differentiation of ES cells with retinol 
acid treatment was performed as previously described 
[53].
Protein extraction, histone extraction, 
immunoprecipitation, and Western blotting
Protein or histone was prepared from MEFs or ESCs for 
Western blot analysis as described [54]. For immunopre-
cipitation assay, 200  μg protein extract from HEK293T 
Fig. 6 A model for Ezh2 variant expression and regulation of PRC2 in histone methylation. Ezh2 transcriptional levels are controlled by E2F and 
a cell-type-specific transcriptional factor (sTF) to fulfill the required histone methylation. The ratio of EZH2 variants is regulated through distinct 
combination of RNA binding proteins (RBPs), which determines the fidelity and efficiency for establishing and maintaining H3K27 methylation. The 
blue rectangles and lines indicate exon 14 of Ezh2 
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cells was incubated with anti-FLAG (F3165, Sigma) or 
anti-HA (A190-108A, Bethyl Labs) conjugated protein 
A/G agarose beads (sc-2003, Santa Cruz Biotechnology). 
FLAG- or HA-tagged full-length coding fragments of 
EZH1, EZH2, PHF1, PHF19, JARID2, and RBBP4 were 
amplified from their cDNAs and cloned into an expres-
sion vector bearing CAG promoter.
Immunostaining on cryosections and mouse ES cells
The immunostaining on testis cryosections is as 
described [54]. Ezh2KO and EzhDKO ES cells were 
transfected with FLAG-tagged EZH variants using 
Xfect™ mESC Transfection Reagent (631320, Clontech) 
according to manufacturer’s instruction. The cells were 
trypsinized and resuspended in ES cell medium 48  h 
post-transfection. ES cells were fixed on slides by adding 
three volumes of 2% PFA (containing 0.1% Triton X-100 
and 100 mM sucrose in 1 × PBS) at 4 °C for 30 min. The 
slides were air-dried and stored at 4 °C for immunofluo-
rescence assays.
Genome editing of Ezh variants by CRISPR‑Cas9
sgRNAs targeting Ezh1 and Ezh2 were cloned into 
pX330-U6-Chimeric_BB-CBh-hSpCas9 (42230, 
Addgene) using Golden Gate assembly cloning strategy 
[55]. The modification of Ezh genes in ES cells followed 
the procedure as described [56]. Briefly, 5 × 104 E14 ES 
cells were cultured on 60 mm dishes for 1 day and then 
transfected with plasmids expressing Cas9 and sgRNAs, 
along with a plasmid expressing PGK-PuroR (Addgene, 
Cat. No. 31937) using FuGENE HD reagent (Promega) 
according to the manufacturer’s instructions. The cells 
were treated with 2  μg/ml puromycin for 2  days and 
recovered in normal culture medium until ES cell colo-
nies grew up. Ezh1 targeted colonies were genotyped 
by PCR and verified by DNA sequencing. Ezh2 targeted 
colonies were screened by Western blot analysis and con-
firmed by DNA sequencing.
Additional files
Additional file 1: Fig. S1. Alternative splicing of exon 4 and exon 8 in 
Ezh2 by RT-PCR analysis in testes at different ages, tissues, embryos, and 
cell lines. 
Additional file 2: Fig. S2. Histone modifications, TF binding, and chro-
matin accessibility around the transcriptional start sites of Ezh2, Eed, and 
Suz12. (a) Histone modifications and chromatin accessibility around Ezh2 
transcriptional start sites. ChIP-seq and ATAC-seq assays were performed 
on spermatocytes isolated from 17-day old testes. (b) Enrichment of E2F1 
at Ezh2 promoter regions in Hela S3 cells. ChIP-seq data was retrieved from 
ENCODE. (c) Enrichment of H3K4me3, H3K27ac, and MYBL1 on Eed and 
Suz12 in p17 spermatocytes by ChIP-seq analysis. 
Additional file 3: Fig. S3. EZH variants in the restoration of H3K27 meth-
ylation in Ezh2KO ES cell lines. (a) Western blot analysis of H3K27 methylai-
ton levels in Ezh knockout ES cells. (b) Ectopic expression of EZH variants 
in EzhDKO ES cells. The cells were harvested two days after transfection for 
Western blot analysis. (c, d) Immunofluorescence analysis of H3K27me2 
and me3 in Ezh2KO ES cells that were transfected with FLAG-tagged EZH 
variants. Scale Bar: 20 μm. 
Additional file 4: Fig. S4. EZH variants interact with other PRC2 subunits. 
(a) The interaction between EZH2 and EED or SUZ12 in ES cells and 
spermatocytes was examined by coimmunoprecipitation assays. (b, c) 
The interaction between EZH variants and PRC2’s accessory subunits was 
examined by coimmunoprecipitation assays. HEK293T cells were cotrans-
fected with each of EZH variants and of accessory subunits and harvested 
for assays two days post-transfection. (d) Comparison of EZH2 protein 
levels between ES cells and spermatocytes by Western blot analysis. 
Nucleolin serves as a control. 
Additional file 5: Table S1. Primer sequences for RT-PCR, quantitative 
real-time PCR, and ChIP-PCR.
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